Global Antibody Therapeutics Market Size study, by Format, by Route of Administration, by Source, by Disease Areas, by End User and Regional Forecasts 2022-2032

Description

The Global Antibody Therapeutics Market is valued approximately at USD 248.79 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 14.89% over the forecast period 2024-2032. Antibody therapeutics represent a class of medical treatments leveraging antibodies to enhance or mimic the immune system's ability to combat diseases. With their high specificity and lower toxicity compared to conventional drugs, antibody therapeutics have emerged as effective treatments for a plethora of conditions, including cancers, autoimmune diseases, and infectious diseases. The growing prevalence of chronic diseases and increasing healthcare expenditure globally have significantly driven the adoption of antibody therapeutics. Despite these challenges, advancements in medical technology are leading to more efficient antibody production, and the emergence of next-generation antibodies along with supportive government initiatives for cancer care are anticipated to provide substantial opportunities for market growth.

The market dynamics are shaped by the significant utilization of monoclonal antibodies due to numerous regulatory approvals, and the growing use of antibody fragments for better tumour penetration and reduced immunogenicity. Bispecific antibodies, with their dual affinity, are also gaining traction for their diverse applications in cancer therapy. Furthermore, the intravenous route remains a common method for delivering antibody therapeutics, ensuring immediate bioavailability and rapid therapeutic action, whereas subcutaneous administration offers the convenience of self-administration and cost-effectiveness. However, the market faces challenges such as high development costs and complex regulatory approval processes, these factors anticipated to restrain market growth between 2024 and 2032.

Geographically, the market analysis covers key regions including North America, Europe, Asia Pacific, Latin America, and the Rest of the World. The North America leads the market driven by a well-established R&D ecosystem and high healthcare expenditure. North America, particularly the United States, boasts a highly advanced healthcare system with a strong focus on research and development. This infrastructure supports extensive clinical trials and facilitates the rapid adoption of new therapies. Various leading pharmaceutical and biotechnology companies, such as Amgen, Genentech (a subsidiary of Roche), and Johnson & Johnson, are based in North America. These companies invest heavily in the development and commercialization of antibody therapeutics. Furthermore, the Asia Pacific region is also anticipated to witness the fastest growth, driven by growing healthcare infrastructure and increased incidence of chronic diseases. Moreover, the European Union also plays a pivotal role in the antibody therapeutics landscape, with strong pharmaceutical industries and comprehensive intellectual property rights frameworks.

Major market players included in this report are:

AbbVie Inc.
AbCellera Biologics Inc.
Adaptimmune Therapeutics PLC
ADC Therapeutics SA
Aenova Holding GmbH
Almac Group Limited
Amgen Inc.
Antikor Biopharma
Argenx SE
Astellas Pharma Inc.
AstraZeneca PLC
Baxter International Inc.
Bayer AG
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.

The detailed segments and sub-segment of the market are explained below:

By Format:

Antibody Fragment
Bispecific Antibody
Monoclonal Antibody
Polyclonal Antibody

By Route of Administration:

Intravenous
Subcutaneous

By Source:

Chimeric
Human
Humanized

By Disease Areas:

Autoimmune & Inflammatory Diseases
Hematology
Immunology
Neurology
Oncology
Osteology

By End User:

Hospitals
Long-term Care Facilities

By Region:

North America:

U.S.
Canada

Europe:

UK
Germany
France
Spain
Italy
ROE

Asia Pacific:

China
India
Japan
Australia
South Korea
RoAPAC

Latin America:

Brazil
Mexico

Middle East & Africa:

Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Antibody Therapeutics Market Executive Summary

1.1. Global Antibody Therapeutics Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Format
- 1.3.2. By Route of Administration
- 1.3.3. By Source
- 1.3.4. By Disease Areas
- 1.3.5. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Antibody Therapeutics Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Antibody Therapeutics Market Dynamics

3.1. Market Drivers
- 3.1.1. Increasing Prevalence of Chronic Diseases
- 3.1.2. Advancements in Medical Technology
3.2. Market Challenges
- 3.2.1. High Development Costs
- 3.2.2. Complex Regulatory Approvals
3.3. Market Opportunities
- 3.3.1. Emergence of Next-Generation Antibodies
- 3.3.2. Supportive Government Initiatives for Cancer Care

Chapter 4. Global Antibody Therapeutics Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Antibody Therapeutics Market Size & Forecasts by Format 2022-2032

5.1. Segment Dashboard
5.2. Global Antibody Therapeutics Market: Format Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Antibody Fragment
- 5.2.2. Bispecific Antibody
- 5.2.3. Monoclonal Antibody
- 5.2.4. Polyclonal Antibody

Chapter 6. Global Antibody Therapeutics Market Size & Forecasts by Route of Administration 2022-2032

6.1. Segment Dashboard
6.2. Global Antibody Therapeutics Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Intravenous
- 6.2.2. Subcutaneous

Chapter 7. Global Antibody Therapeutics Market Size & Forecasts by Source 2022-2032

7.1. Segment Dashboard
7.2. Global Antibody Therapeutics Market: Source Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Chimeric
- 7.2.2. Human
- 7.2.3. Humanized

Chapter 8. Global Antibody Therapeutics Market Size & Forecasts by Disease Areas 2022-2032

8.1. Segment Dashboard
8.2. Global Antibody Therapeutics Market: Disease Areas Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 8.2.1. Autoimmune & Inflammatory Diseases
- 8.2.2. Hematology
- 8.2.3. Immunology
- 8.2.4. Neurology
- 8.2.5. Oncology
- 8.2.6. Osteology

Chapter 9. Global Antibody Therapeutics Market Size & Forecasts by End User 2022-2032

9.1. Segment Dashboard
9.2. Global Antibody Therapeutics Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 9.2.1. Hospitals
- 9.2.2. Long-term Care Facilities

Chapter 10. Global Antibody Therapeutics Market Size & Forecasts by Region 2022-2032

10.1. North America Antibody Therapeutics Market
- 10.1.1. U.S. Antibody Therapeutics Market
  - 10.1.1.1. Format breakdown size & forecasts, 2022-2032
  - 10.1.1.2. Route of Administration breakdown size & forecasts, 2022-2032
  - 10.1.1.3. Source breakdown size & forecasts, 2022-2032
  - 10.1.1.4. Disease Areas breakdown size & forecasts, 2022-2032
  - 10.1.1.5. End User breakdown size & forecasts, 2022-2032
- 10.1.2. Canada Antibody Therapeutics Market
  - 10.1.2.1. Format breakdown size & forecasts, 2022-2032
  - 10.1.2.2. Route of Administration breakdown size & forecasts, 2022-2032
  - 10.1.2.3. Source breakdown size & forecasts, 2022-2032
  - 10.1.2.4. Disease Areas breakdown size & forecasts, 2022-2032
  - 10.1.2.5. End User breakdown size & forecasts, 2022-2032
10.2. Europe Antibody Therapeutics Market
- 10.2.1. UK Antibody Therapeutics Market
  - 10.2.1.1. Format breakdown size & forecasts, 2022-2032
  - 10.2.1.2. Route of Administration breakdown size & forecasts, 2022-2032
  - 10.2.1.3. Source breakdown size & forecasts, 2022-2032
  - 10.2.1.4. Disease Areas breakdown size & forecasts, 2022-2032
  - 10.2.1.5. End User breakdown size & forecasts, 2022-2032
- 10.2.2. Germany Antibody Therapeutics Market
  - 10.2.2.1. Format breakdown size & forecasts, 2022-2032
  - 10.2.2.2. Route of Administration breakdown size & forecasts, 2022-2032
  - 10.2.2.3. Source breakdown size & forecasts, 2022-2032
  - 10.2.2.4. Disease Areas breakdown size & forecasts, 2022-2032
  - 10.2.2.5. End User breakdown size & forecasts, 2022-2032
- 10.2.3. France Antibody Therapeutics Market
  - 10.2.3.1. Format breakdown size & forecasts, 2022-2032
  - 10.2.3.2. Route of Administration breakdown size & forecasts, 2022-2032
  - 10.2.3.3. Source breakdown size & forecasts, 2022-2032
  - 10.2.3.4. Disease Areas breakdown size & forecasts, 2022-2032
  - 10.2.3.5. End User breakdown size & forecasts, 2022-2032
- 10.2.4. Spain Antibody Therapeutics Market
  - 10.2.4.1. Format breakdown size & forecasts, 2022-2032
  - 10.2.4.2. Route of Administration breakdown size & forecasts, 2022-2032
  - 10.2.4.3. Source breakdown size & forecasts, 2022-2032
  - 10.2.4.4. Disease Areas breakdown size & forecasts, 2022-2032
  - 10.2.4.5. End User breakdown size & forecasts, 2022-2032
- 10.2.5. Italy Antibody Therapeutics Market
  - 10.2.5.1. Format breakdown size & forecasts, 2022-2032
  - 10.2.5.2. Route of Administration breakdown size & forecasts, 2022-2032
  - 10.2.5.3. Source breakdown size & forecasts, 2022-2032
  - 10.2.5.4. Disease Areas breakdown size & forecasts, 2022-2032
  - 10.2.5.5. End User breakdown size & forecasts, 2022-2032
- 10.2.6. Rest of Europe Antibody Therapeutics Market
  - 10.2.6.1. Format breakdown size & forecasts, 2022-2032
  - 10.2.6.2. Route of Administration breakdown size & forecasts, 2022-2032
  - 10.2.6.3. Source breakdown size & forecasts, 2022-2032
  - 10.2.6.4. Disease Areas breakdown size & forecasts, 2022-2032
  - 10.2.6.5. End User breakdown size & forecasts, 2022-2032
10.3. Asia-Pacific Antibody Therapeutics Market
- 10.3.1. China Antibody Therapeutics Market
  - 10.3.1.1. Format breakdown size & forecasts, 2022-2032
  - 10.3.1.2. Route of Administration breakdown size & forecasts, 2022-2032
  - 10.3.1.3. Source breakdown size & forecasts, 2022-2032
  - 10.3.1.4. Disease Areas breakdown size & forecasts, 2022-2032
  - 10.3.1.5. End User breakdown size & forecasts, 2022-2032
- 10.3.2. India Antibody Therapeutics Market
  - 10.3.2.1. Format breakdown size & forecasts, 2022-2032
  - 10.3.2.2. Route of Administration breakdown size & forecasts, 2022-2032
  - 10.3.2.3. Source breakdown size & forecasts, 2022-2032
  - 10.3.2.4. Disease Areas breakdown size & forecasts, 2022-2032
  - 10.3.2.5. End User breakdown size & forecasts, 2022-2032
- 10.3.3. Japan Antibody Therapeutics Market
  - 10.3.3.1. Format breakdown size & forecasts, 2022-2032
  - 10.3.3.2. Route of Administration breakdown size & forecasts, 2022-2032
  - 10.3.3.3. Source breakdown size & forecasts, 2022-2032
  - 10.3.3.4. Disease Areas breakdown size & forecasts, 2022-2032
  - 10.3.3.5. End User breakdown size & forecasts, 2022-2032
- 10.3.4. Australia Antibody Therapeutics Market
  - 10.3.4.1. Format breakdown size & forecasts, 2022-2032
  - 10.3.4.2. Route of Administration breakdown size & forecasts, 2022-2032
  - 10.3.4.3. Source breakdown size & forecasts, 2022-2032
  - 10.3.4.4. Disease Areas breakdown size & forecasts, 2022-2032
  - 10.3.4.5. End User breakdown size & forecasts, 2022-2032
- 10.3.5. South Korea Antibody Therapeutics Market
  - 10.3.5.1. Format breakdown size & forecasts, 2022-2032
  - 10.3.5.2. Route of Administration breakdown size & forecasts, 2022-2032
  - 10.3.5.3. Source breakdown size & forecasts, 2022-2032
  - 10.3.5.4. Disease Areas breakdown size & forecasts, 2022-2032
  - 10.3.5.5. End User breakdown size & forecasts, 2022-2032
- 10.3.6. Rest of Asia Pacific Antibody Therapeutics Market
  - 10.3.6.1. Format breakdown size & forecasts, 2022-2032
  - 10.3.6.2. Route of Administration breakdown size & forecasts, 2022-2032
  - 10.3.6.3. Source breakdown size & forecasts, 2022-2032
  - 10.3.6.4. Disease Areas breakdown size & forecasts, 2022-2032
  - 10.3.6.5. End User breakdown size & forecasts, 2022-2032
10.4. Latin America Antibody Therapeutics Market
- 10.4.1. Brazil Antibody Therapeutics Market
  - 10.4.1.1. Format breakdown size & forecasts, 2022-2032
  - 10.4.1.2. Route of Administration breakdown size & forecasts, 2022-2032
  - 10.4.1.3. Source breakdown size & forecasts, 2022-2032
  - 10.4.1.4. Disease Areas breakdown size & forecasts, 2022-2032
  - 10.4.1.5. End User breakdown size & forecasts, 2022-2032
- 10.4.2. Mexico Antibody Therapeutics Market
  - 10.4.2.1. Format breakdown size & forecasts, 2022-2032
  - 10.4.2.2. Route of Administration breakdown size & forecasts, 2022-2032
  - 10.4.2.3. Source breakdown size & forecasts, 2022-2032
  - 10.4.2.4. Disease Areas breakdown size & forecasts, 2022-2032
  - 10.4.2.5. End User breakdown size & forecasts, 2022-2032
- 10.4.3. Rest of Latin America Antibody Therapeutics Market
  - 10.4.3.1. Format breakdown size & forecasts, 2022-2032
  - 10.4.3.2. Route of Administration breakdown size & forecasts, 2022-2032
  - 10.4.3.3. Source breakdown size & forecasts, 2022-2032
  - 10.4.3.4. Disease Areas breakdown size & forecasts, 2022-2032
  - 10.4.3.5. End User breakdown size & forecasts, 2022-2032
10.5. Middle East & Africa Antibody Therapeutics Market
- 10.5.1. Saudi Arabia Antibody Therapeutics Market
  - 10.5.1.1. Format breakdown size & forecasts, 2022-2032
  - 10.5.1.2. Route of Administration breakdown size & forecasts, 2022-2032
  - 10.5.1.3. Source breakdown size & forecasts, 2022-2032
  - 10.5.1.4. Disease Areas breakdown size & forecasts, 2022-2032
  - 10.5.1.5. End User breakdown size & forecasts, 2022-2032
- 10.5.2. South Africa Antibody Therapeutics Market
  - 10.5.2.1. Format breakdown size & forecasts, 2022-2032
  - 10.5.2.2. Route of Administration breakdown size & forecasts, 2022-2032
  - 10.5.2.3. Source breakdown size & forecasts, 2022-2032
  - 10.5.2.4. Disease Areas breakdown size & forecasts, 2022-2032
  - 10.5.2.5. End User breakdown size & forecasts, 2022-2032
- 10.5.3. Rest of Middle East & Africa Antibody Therapeutics Market
  - 10.5.3.1. Format breakdown size & forecasts, 2022-2032
  - 10.5.3.2. Route of Administration breakdown size & forecasts, 2022-2032
  - 10.5.3.3. Source breakdown size & forecasts, 2022-2032
  - 10.5.3.4. Disease Areas breakdown size & forecasts, 2022-2032
  - 10.5.3.5. End User breakdown size & forecasts, 2022-2032

Chapter 11. Competitive Intelligence

11.1. Key Company SWOT Analysis
- 11.1.1. AbbVie Inc.
- 11.1.2. AbCellera Biologics Inc.
- 11.1.3. Adaptimmune Therapeutics PLC.
11.2. Top Market Strategies
11.3. Company Profiles
- 11.3.1. AbbVie Inc.
  - 11.3.1.1. Key Information
  - 11.3.1.2. Overview
  - 11.3.1.3. Financial (Subject to Data Availability)
  - 11.3.1.4. Product Summary
  - 11.3.1.5. Market Strategies
- 11.3.2. AbCellera Biologics Inc.
- 11.3.3. Adaptimmune Therapeutics PLC.
- 11.3.4. ADC Therapeutics SA
- 11.3.5. Aenova Holding GmbH
- 11.3.6. Almac Group Limited
- 11.3.7. Amgen Inc.
- 11.3.8. Antikor Biopharma
- 11.3.9. Argenx SE
- 11.3.10. Astellas Pharma Inc.
- 11.3.11. AstraZeneca PLC
- 11.3.12. Baxter International Inc.
- 11.3.13. Bayer AG
- 11.3.14. Becton, Dickinson and Company
- 11.3.15. Bio-Rad Laboratories, Inc.

Chapter 12. Research Process

12.1. Research Process
- 12.1.1. Data Mining
- 12.1.2. Analysis
- 12.1.3. Market Estimation
- 12.1.4. Validation
- 12.1.5. Publishing
12.2. Research Attributes